<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2974">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04471701</url>
  </required_header>
  <id_info>
    <org_study_id>EPICOVID19_2020</org_study_id>
    <nct_id>NCT04471701</nct_id>
  </id_info>
  <brief_title>Italian Web-based Cross-sectional Survey on COVID-19</brief_title>
  <acronym>EPICOVID19</acronym>
  <official_title>Italian Web-based EPICOVID19 Cross-sectional Survey</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Biomedical Technologies-National Research Council, Italy</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Research Council, Institute of Clinical Physiology, Italy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institute of Neuroscience-National Research Council</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Milan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Italian Society of Geriatrics and Gerontology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Italian Society of Infectious and Tropical Diseases</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institute of Biomedical Technologies-National Research Council, Italy</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The outbreak of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) that started in&#xD;
      late December 2019 in the Hubei province of China caused millions of cases worldwide in just&#xD;
      a few months, and evolved into a real pandemic.&#xD;
&#xD;
      However, only approximately 20% of SARS-CoV-2 infected patients required intensive on&#xD;
      sub-intensice medical care and the remained experience mild or subclinical form of the&#xD;
      disease that did not require hospital admission and a relatively high percentage (40 to 45%)&#xD;
      remained asymptomatic.&#xD;
&#xD;
      Understanding the occurrence of SARS-CoV-2-like infectious in a large non-hospitalized&#xD;
      population, when the epidemic peak was occurring in Italy, is of paramount importance but&#xD;
      data are scarce.&#xD;
&#xD;
      The goal of this research project is to estimate the number of suspected cases of COVID-19&#xD;
      and to investigate the role of the potential factors associated with SARS-CoV-2 infection in&#xD;
      a large Italian sample of respondents living in Italy during the lockdown (started in Italy&#xD;
      on 9 March 2020).&#xD;
&#xD;
      EPICOVID19 is an Italian countrywide self-administered cross-sectional web-based survey on&#xD;
      adult volunteers launched on April 13, 2020.&#xD;
&#xD;
      The on-line questionnaire has been developed starting from the available literature and&#xD;
      implemented using an open source platform focusing on beahvioural and clinical features of&#xD;
      participants.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The COVID-19 pandemic is posing an unprecedented threat worldwide, which have been&#xD;
      experiencing widespread transmission of the virus in the community for several weeks.&#xD;
&#xD;
      During the epidemic peak, epidemiological surveillance strategies were mainly based on the&#xD;
      testing of symptomatic patients with serious diseases requiring hospitalization and intensive&#xD;
      or sub-intensive medical care. This has underestimated the real spread of the infection in&#xD;
      the mild symptomatic (paucisymptomatic) or asymptomatic individuals or in specific group of&#xD;
      persons with limited access to testing.&#xD;
&#xD;
      EPICOVID19 was developed and launched to accomplish the following objectives: i) to estimate&#xD;
      the number of suspected cases of COVID-19 in the general population, and ii) to investigate&#xD;
      the role of the potential factors associated with SARS-CoV-2 infection in adult volunteers&#xD;
      living in Italy during the lockdown.&#xD;
&#xD;
      EPICOVID19 is a national Italian anonymous self-administered internet-based survey that was&#xD;
      carried out using a cross-sectional research design in a convenience sample of adult&#xD;
      volunteers (18+ years old) living in Italy during the lockdown. The survey was launched on 13&#xD;
      April 2020.&#xD;
&#xD;
      In order to enrol as many subjects as possible, the link to the electronic survey was&#xD;
      uploaded, shared and disseminated via several channels: e-mails, social media platforms&#xD;
      (Facebook, Twitter, Instagram, Whatsapp), press releases, internet pages, local radio and TV&#xD;
      stations, and institutional websites that called upon volunteers to contact the study website&#xD;
      https://epicovid19.itb.cnr.it/.&#xD;
&#xD;
      The EPICOVID19 study was established as a collaboration of a working work including&#xD;
      epidemiologists, clinicians, biostatisticians, and public health professionals to improve&#xD;
      SARS-CoV-2-related knowledge. The steering group tested the survey for a period of 2 weeks&#xD;
      before starting to share the public link to the general population on April 13, 2020. The&#xD;
      participants are asked to complete the self-administered 38-item questionnaire, which&#xD;
      contained mainly mandatory and closed questions that is divided into six sections.&#xD;
&#xD;
      EPICOVID19 was designed by the steering group after a literature review of existing research&#xD;
      into COVID-19. To guarantee the maximal comparability to other large epidemiological studies,&#xD;
      several questions was chosen based on standardized and validated questionnaires. The survey&#xD;
      was adapted to the national context and implemented using the European Commission's&#xD;
      open-source official EUSurvey management tool (https://ec.europa.eu/eusurvey).&#xD;
&#xD;
      The survey includes an introductory page briefly describing the rational and the aims of the&#xD;
      study, the consortium, and the option to provide or not the consent to participate.&#xD;
&#xD;
      The first section of the questionnaire investigates the socio-demographic characteristics of&#xD;
      the respondents: sex at birth, birth year, ethnicity, user's postal code and municipality of&#xD;
      residence, educational level, employment status, and current (or last) occupation.&#xD;
&#xD;
      The second section of the questionnaire investigates the clinical features: SARS-CoV-2&#xD;
      infection-like symptoms and the month of onset of the first symptoms, pre-existing diseases,&#xD;
      other conditions to refer, vaccines, past and current use of medication and supplements, and,&#xD;
      for females only, use of contraception or hormone replacement therapy at menopause, and&#xD;
      number of completed pregnancies, when applicable. Data about close contact with confirmed or&#xD;
      suspected cases, contacts with general practitioner and/or national emergency numbers,&#xD;
      molecular tests and results (if available), hospitalization for confirmed or suspected&#xD;
      SARS-CoV-2-like infection, and other possible risk conditions to refer, are also collected.&#xD;
&#xD;
      The third section of the questionnaire is focused on the personal characteristics and health&#xD;
      status of respondents: questions about self-perceived health status and risk perception .&#xD;
&#xD;
      The fourth section investigates the housing conditions: population density in the area of&#xD;
      residence, self-reported traffic intensity in the area of residence, number of rooms, number&#xD;
      of co-habitants, and presence of at-risk co-habitants.&#xD;
&#xD;
      The fifth section focuses on lifestyles: daily mean number of contacts, smoking habit, and&#xD;
      frequency of weekly physical activity.&#xD;
&#xD;
      The sixth section investigates the behaviours following the lockdown: job conditions, number&#xD;
      of times of going out per week, and use of public transportation.&#xD;
&#xD;
      The Ethics Committee of the Istituto Nazionale per le Malattie Infettive I.R.C.C.S. Lazzaro&#xD;
      Spallanzani (Protocol No. 70, 12/4/2020) approved the EPICOVID19 study protocol. When they&#xD;
      first accessed the on-line platform, the participants were informed of the purpose of the&#xD;
      study, the data to be collected, and the method of storage. The data were handled and stored&#xD;
      in accordance with the European Union General Data Protection Regulation (EU GDPR) 2016/679&#xD;
      (http://gdpr-info.eu/), and data transfer was safeguarded by means of encrypting/decrypting&#xD;
      and password protection. The study was conducted according to the Declaration of Helsinki.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 13, 2020</start_date>
  <completion_date type="Anticipated">August 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants (%) with COVID-19-like symptoms</measure>
    <time_frame>3 months (July 2020) after initial data collection (April 2020)</time_frame>
    <description>Measured by using answers on the Clinical evaluation section of the questionnaire: Fever &gt; 37.5 Â°C for at least 3 consecutive days; cough; sore throat/rhinorrea; headache; myalgia; olfactory/taste disorders; shortness of breath; chest pain; tachycardia; gastrointestinal disorders; conjunctivitis.&#xD;
Variables on symptomatology will be created by considering each symtom singularly and by combining them using a priori definition (e.g. WHO) and a posteriori approach (based on EPICOVID19 data).&#xD;
Logistic regression models will be applied to assess the measurements of association between exposures of interest and COVID-19-like symptoms by estimating the aOR and 95%CI.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants (%) with SARS-CoV-2 nasopharyngeal swab (NPS) test positivity</measure>
    <time_frame>3 months (July 2020) after initial data collection (April 2020)</time_frame>
    <description>Measured by using answers collected thorugh the on-line questionnaire about molecular NPS tests results.&#xD;
Logistic regression models will be applied to assess the measurements of association between exposures of interest and SARS-CoV-2 NPS positivity versus negativity by estimating the odds ratios (aOR) and 95% Confidence Intervals (CI).</description>
  </primary_outcome>
  <enrollment type="Anticipated">200000</enrollment>
  <condition>Covid19</condition>
  <condition>SARS-CoV Infection</condition>
  <condition>Survey, Family Life</condition>
  <condition>Epidemic Disease</condition>
  <condition>Self-Assessment</condition>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Environmental exposure and clinical features</intervention_name>
    <description>Environmental exposures and clinical features are measured by means of a self-administered 38-item on-line questionnaire containing mainly mandatory and closed questions divided into six sections: i) socio-demographic data; ii) clinical evaluation; iii) personal characteristics and health status; iv) housing conditions; v) lifestyle; and vi) behaviours following the lockdown.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        EPICOVID19 is a national Italian internet-based survey that targets adult volunteers (males&#xD;
        and females &gt;=18 years old) living in Italy during the lockdown (started in Italy on 9&#xD;
        March 2020). In order to enrol as many subjects as possible, the survey was promoted using&#xD;
        social media (Facebook, Twitter, Instagram, Whatsapp), press releases, internet pages,&#xD;
        local radio and TV stations, and institutional websites that called upon volunteers to&#xD;
        contact the study website (https://epicovid19.itb.cnr.it/).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age of &gt;=18 years;&#xD;
&#xD;
          -  access to a mobile phone, computer, or tablet with internet connectivity;&#xD;
&#xD;
          -  on-line consent to participate in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  age of &lt;18 years;&#xD;
&#xD;
          -  without access to a mobile phone, computer, or tablet with internet connectivity;&#xD;
&#xD;
          -  not provide on-line consent to participate in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Federica Prinelli, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Biomedical Technologies-National Research Council</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fulvio Adorni, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Biomedical Technologies-National Research Council</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Federica Prinelli, PhD</last_name>
    <phone>+39 0226422629</phone>
    <email>federica.prinelli@itb.cnr.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Fulvio Adorni, MPH</last_name>
    <phone>+39 0226422629</phone>
    <email>fulvio.adorni@itb.cnr.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institute of Biomedical Technologies-National Research Council</name>
      <address>
        <city>Segrate</city>
        <state>MI</state>
        <zip>20090</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Federica Prinelli, PhD</last_name>
      <phone>+39 0226422629</phone>
      <email>federica.prinelli@itb.cnr.it</email>
    </contact>
    <contact_backup>
      <last_name>Fulvio Adorni, MPH</last_name>
      <phone>+39 0226422629</phone>
      <email>fulvio.adorni@itb.cnr.it</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>http://epicovid19.itb.cnr.it/</url>
    <description>Institutional web-site of ITB-CNR</description>
  </link>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 14, 2020</study_first_submitted>
  <study_first_submitted_qc>July 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 15, 2020</study_first_posted>
  <last_update_submitted>July 14, 2020</last_update_submitted>
  <last_update_submitted_qc>July 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SARS-CoV-2;COVID-19;voluntary respondents;web-based survey</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

